Exametazime Hmpao
Loading...Exametazime Hmpao Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
There is currently no warning information available for this product. We apologize for any inconvenience.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
Exametazime is a diagnostic agent used as an adjunct in the detection of altered cerebral perfusion in stroke patients and is also indicated for white blood cell labeling as an adjunct in the localization of abdominal infections and inflammatory bowel disease
History
There is currently no drug history available for this drug.
Other Information
AnazaoHealth’s compounded Exametazime vial is a sterile, non-pyrogenic preparation that consists of a lyophilized mixture of 1 mg of Exametazime, 6.75 mg of Sodium Chloride, 11.4 µg of Stannous Chloride Dihydrate and is maintained under an inert nitrogen atmosphere. The kit also contains a vial of Cobalt Chloride, which contains 0.3 mg of cobalt chloride hexahydrate, or Methylene Blue 1% (methylene blue 10 mg/mL) and Phosphate Buffer (monobasic sodium phosphate, sodium chloride, dibasic sodium phosphate This kit contains no antimicrobial preservative
Sources
Exametazime Hmpao Manufacturers
-
Anazaohealth Corporation
![Exametazime Hmpao (Exametazime) Injection, Powder, Lyophilized, For Solution [Anazaohealth Corporation]](/wp-content/themes/bootstrap/assets/img/loading2.gif)
Exametazime Hmpao | Anazaohealth Corporation
Cerebral Scintigraphy
The recommended dose range for IV administration is 10 to 20 mCi (370 to 740 MBq).
Leukocyte (WBC) Labeling
The recommended dose range for IV administration is 7 to 25 mCi (259 to 925 MBq)
Login To Your Free Account